Folgen
Roger Paredes, MD, PhD
Roger Paredes, MD, PhD
Infectious Diseases Department & irsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol
Bestätigte E-Mail-Adresse bei irsicaixa.es
Titel
Zitiert von
Zitiert von
Jahr
Remdesivir for the treatment of Covid-19
JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ...
New England Journal of Medicine 383 (19), 1813-1826, 2020
44112020
Remdesivir for the treatment of Covid-19—preliminary report
JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ...
New England Journal of Medicine 383 (19), 1813-1836, 2020
23682020
Baricitinib plus remdesivir for hospitalized adults with Covid-19
AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ...
New England Journal of Medicine 384 (9), 795-807, 2021
12722021
2011 update of the drug resistance mutations in HIV-1
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ...
Topics in antiviral medicine 19 (4), 156, 2011
12272011
2015 update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Top Antivir Med 23 (4), 132-41, 2015
948*2015
Special contribution 2014 Update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 22 (3), 642, 2014
948*2014
Special contribution 2014 Update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 22 (3), 642, 2014
948*2014
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
M J Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ...
Nature medicine 16 (4), 460-465, 2010
6272010
Early remdesivir to prevent progression to severe Covid-19 in outpatients
RL Gottlieb, CE Vaca, R Paredes, J Mera, BJ Webb, G Perez, G Oguchi, ...
New England Journal of Medicine 386 (4), 305-315, 2022
4762022
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …
L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ...
The Lancet infectious diseases 11 (5), 363-371, 2011
4372011
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis
JZ Li, R Paredes, HJ Ribaudo, ES Svarovskaia, KJ Metzner, MJ Kozal, ...
Jama 305 (13), 1327-1335, 2011
3932011
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population
AJ Rodger, R Lodwick, M Schechter, S Deeks, J Amin, R Gilson, ...
Aids 27 (6), 973-979, 2013
3892013
Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
A Tuldrà, CR Fumaz, MJ Ferrer, R Bayés, A Arnó, M Balagué, A Bonjoch, ...
Journal of acquired immune deficiency syndromes (1999) 25 (3), 221-228, 2000
3442000
Gut microbiota linked to sexual preference and HIV infection
M Noguera-Julian, M Rocafort, Y Guillén, J Rivera, M Casadellà, P Nowak, ...
EBioMedicine 5, 135-146, 2016
3242016
Update of the drug resistance mutations in HIV-1: March 2013
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ...
Topics in antiviral medicine 21 (1), 6, 2013
3192013
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study
R Paredes, A Mocroft, O Kirk, A Lazzarin, SE Barton, J Van Lunzen, ...
Archives of internal medicine 160 (8), 1123-1132, 2000
2942000
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ...
Jama 326 (6), 499-518, 2021
2772021
A neutralizing monoclonal antibody for hospitalized patients with Covid-19
ACTIV-3/TICO LY-CoV555 Study Group
New England Journal of Medicine 384 (10), 905-914, 2021
2552021
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo
AMN Tsibris, B Korber, R Arnaout, C Russ, CC Lo, T Leitner, B Gaschen, ...
PloS one 4 (5), e5683, 2009
2532009
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
L Ruiz, J Martinez-Picado, J Romeu, R Paredes, MK Zayat, S Marfil, ...
Aids 14 (4), 397-403, 2000
2492000
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20